Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals announced a private offering of $1.0 billion in exchangeable senior notes due 2032, with an option for purchasers to acquire an additional $150.0 million aggregate principal amount. The company intends to use the net proceeds for general corporate purposes and concurrently plans to repurchase up to $225.0 million of its ordinary shares using existing cash on hand.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.